MENLO PARK, CA and PARIS, FRANCE, February 1, 2016 – Avalanche Biotechnologies, Inc. (“Avalanche”) (Nasdaq: AAVL) and Annapurna Therapeutics SAS (“Annapurna”), a privately held biopharmaceutical company, today announced that they have entered into a definitive agreement providing for the acquisition of all outstanding shares of Annapurna by Avalanche in exchange for approximately 17.6 million newly issued shares of Avalanche common stock.
Read the entire Press Release HERE
